得力生注射液联合健择对肝癌HepG2细胞株增殖与凋亡的影响

Antiproliferative and apoptosis effect of Delisheng injection alone and combined with gemcitabine on HepG2 cells

目的:探讨得力生注射液(DLS)、健择(GEM)单药及联合作用对人肝癌HepG2细胞株的增殖抑制和诱导凋亡作用。方法:MTT法观察不同浓度得力生注射液、健择单药及联合应用对HepG2细胞株生长的抑制作用;采用流式细胞仪检测上述药物单独或联合应用对HepG2细胞株凋亡率的影响以及得力生注射液对细胞周期的影响。结果:得力生注射液、健择单药及联合作用对HepG2细胞株的抑制作用均呈明显的剂量与时间依赖关系。均可诱导细胞凋亡。联用时有协同作用。得力生注射液主要使HepG2细胞株阻滞于G1期,与对照组比较,实验组细胞凋亡率增高(P<0.05)。结论:得力生注射液、健择能够抑制人肝癌HepG2细胞增殖并诱导凋亡。两药联合有协同作用。

Objective：To observe the combination effects of Delisheng injection and gemcitabine in human hepatocellular carcinoma cell line HepG2 in vitro.Methods：Cell growth inhibition was assessed by MTT and apoptosis and cell cycle was observed by flow cytometry.Results：Delisheng,GEM,Delisheng ＋ GEM produced time-and dose dependent inhibition of HepG2 cells.Delisheng ＋ GEM showed a higher apoptosis rate induction than Delisheng or GEM alone.Delisheng caused cell cycle arrest at G1 phase and significantly increased the apoptosis rate of the HepG2 cell line（P 0.05）.Conclusion：Delisheng injection and gemcitabine both have the effect of inhibition on the proliferation and induction of apoptosis in human hepatocellular carcinoma cell line HepG2 cells.Combining application can enhance apoptosis.